Invasive fungal infections in neonates: a review

Pediatr Res. 2022 Jan;91(2):404-412. doi: 10.1038/s41390-021-01842-7. Epub 2021 Dec 9.

Abstract

Invasive fungal infections remain the leading causes of morbidity and mortality in neonates, especially preterm and very low birth weight infants. Most invasive fungal infections are due to Candida or Aspergillus species, and other fungi are increasingly reported and described. Appropriate identification and treatment are required to augment activity and reduce the toxicity of antifungal drugs. Successful use of antifungals in the vulnerable neonatal population is important for both prevention and treatment of infection. Strategies for prevention, including prophylactic antifungal therapy as well as reducing exposure to modifiable risk factors, like limiting antibiotic exposure, discontinuation of central catheters, and hand hygiene are key techniques to prevent and decrease rates of invasive fungal infections. In conclusion, this is a review of the most common causes, prevention strategies, prophylaxis, and treatment of invasive fungal infections in neonates.

Publication types

  • Review

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Humans
  • Immunocompromised Host
  • Infant, Newborn
  • Infant, Newborn, Diseases / diagnosis
  • Infant, Newborn, Diseases / drug therapy*
  • Infant, Newborn, Diseases / microbiology
  • Infant, Newborn, Diseases / physiopathology
  • Invasive Fungal Infections / diagnosis
  • Invasive Fungal Infections / drug therapy*
  • Invasive Fungal Infections / microbiology
  • Invasive Fungal Infections / physiopathology
  • Risk Factors

Substances

  • Antifungal Agents